干扰素治疗慢性乙型肝炎对血清自身抗体的影响
|
摘要
目的比较普通干扰素-α(IFN-α)和聚乙二醇干扰素-α(peg IFN-α)治疗慢性乙型肝炎(CHB)的临床效果及对血清自身抗体的影响。方法将首次接受抗病毒治疗慢性乙型病毒性肝炎(CHB)患者124例根据入院先后顺序分为观察组和对照组各62例。观察组采用peg IFN-α治疗,对照组采用IFN-α治疗。比较2组HBs Ag、HBe Ag、HBV-DNA转阴情况、血清ALT水平及血清IFN抗体水平。结果观察组HBs Ag、HBe Ag和HBV-DNA转阴率均高于对照组,差异均有统计学意义(P <0. 05)。观察组血清ALT水平低于对照组,差异有统计学意义(P <0. 05);2组血清IFN抗体水平比较,差异无统计学意义(P> 0. 05)。结论 peg IFN-α可提高CHB的HBs Ag、HBe Ag和HBVDNA转阴率,改善肝功能,与IFN抗体水平升高无关。
Objective To compare the clinical effect of pegylated interferon-α( peg IFN-α) and interferon-α( IFN-α)in chronic hepatitis B( CHB) patients and the serum autoantibody expression. Methods 124 patients with chronic hepatitis B( CHB) who received antiviral therapy for the first time were divided into observation group and control group according to the order of admission,each of 62 cases. Observation group was treated with peg IFN-α,and control group was treated with IFN-α.The HBs Ag,HBe Ag,HBV-DNA negative conditions,serum ALT levels and serum IFN antibody levels were compared of two groups. Results The negative rates of HBs Ag,HBe Ag and HBV-DNA in observation group were higher than those in control group,the difference was statistically significant( P < 0. 05). The serum ALT level in observation group was lower than that in control group,and the difference was statistically significant( P < 0. 05). There was no significant difference in serum IFN antibody levels between two groups( P > 0. 05). Conclusion Peg IFN-α can increase the HBs Ag,HBe Ag and HBV-DNA negative rate of CHB,improve liver function,and has nothing to do with elevated IFN antibody levels.
Objective To compare the clinical effect of pegylated interferon-α( peg IFN-α) and interferon-α( IFN-α)in chronic hepatitis B( CHB) patients and the serum autoantibody expression. Methods 124 patients with chronic hepatitis B( CHB) who received antiviral therapy for the first time were divided into observation group and control group according to the order of admission,each of 62 cases. Observation group was treated with peg IFN-α,and control group was treated with IFN-α.The HBs Ag,HBe Ag,HBV-DNA negative conditions,serum ALT levels and serum IFN antibody levels were compared of two groups. Results The negative rates of HBs Ag,HBe Ag and HBV-DNA in observation group were higher than those in control group,the difference was statistically significant( P < 0. 05). The serum ALT level in observation group was lower than that in control group,and the difference was statistically significant( P < 0. 05). There was no significant difference in serum IFN antibody levels between two groups( P > 0. 05). Conclusion Peg IFN-α can increase the HBs Ag,HBe Ag and HBV-DNA negative rate of CHB,improve liver function,and has nothing to do with elevated IFN antibody levels.
引文
[1]张国民,孙校金,王富珍,等.中国18~59岁人群乙型病毒性肝炎流行病学特征分析及乙型肝炎疫苗免疫策略探讨[J].中国疫苗和免疫,2013,19(3):266-270.
[2]聂尚燕,赵蕾,麻慧宇,等.恩替卡韦联合聚乙二醇干扰素α-2a治疗慢性乙型病毒性肝炎的临床疗效及安全性[J].中国临床药理学杂志,2015,31(23):2281-2283.DOI:10.13699/j.cnki.1001-6821.2015.23.001.
[3]杨龙,杨阳,陈志勇,等.聚乙二醇干扰素α-2a治疗多种核苷(酸)类药物耐药慢性乙型肝炎的疗效[J].实用医学杂志,2014,30(3):503-504.DOI:10.3969/j.issn.1006-5725.2014.03.059.
[4]谢志伟,周福元,周元平.干扰素α和恩替卡韦治疗HBeAg阳性慢性乙型肝炎疗效的预测因素[J].南方医科大学学报,2013,33(6):878-881.DOI:10.3969/j.issn.1673-4254.2013.06.19.
[5]李剑萍,关玉娟,洪文昕,等.聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎患者疗效及其影响因素分析[J].实用肝脏病杂志,2014,17(2):149-153.DOI:10.3969/j.issn.1672-5069.2014.02.010.
[6]张文杰,李朝霞,田淑菊,等.干扰素α治疗慢性丙型肝炎干扰素中和抗体的产生及其对抗病毒治疗疗效的影响[J].临床肝胆病杂志,2010,26(1):27-30.DOI:10.3969/j.issn.1001-5256.2010.01.008.
[7]王慧,林栋栋,李长缨,等.慢性乙型肝炎干扰素治疗与KIR基因多态性及干扰素抗体的相关性研究[J].中国医学创新,2017,14(6):20-24.DOI:10.3969/j.issn.1674-4985.2017.06.006.
[8]郑建铭,朱梦琪,陈明泉,等.聚乙二醇干扰素治疗慢性乙型肝炎患者血清干扰素浓度及其抗体水平的变化[J].肝脏,2012,17(12):840-842.DOI:10.3969/j.issn.1008-1704.2012.12.002.
[9]丁艾昆,郭利伟,欧阳瑞春,等.聚乙二醇干扰素a-2a联合核苷(酸)类似物治疗HBeAg阳性慢性乙型肝炎的疗效观察[J].中国病原生物学杂志,2015,10(3):272-276.DOI:10.13350/j.cjpb.150320.
[10]李茂英,袁学兰,张大志.聚乙二醇干扰素单用或联合核苷(酸)类似物治疗慢性乙型肝炎疗效与安全性的荟萃分析[J].中华肝脏病杂志,2012,20(6):442-447.DOI:10.3760/cma.j.issn.1007-3418.2012.06.013.
[11]屈晓威,庞秋霞,赵菊梅,等.延安市病毒性肝炎干扰素抗体的检测分析[J].延安大学学报(医学科学版),2009,7(3):3-4.DOI:10.3969/j.issn.1672-2639.2009.03.002.
[12]刘劲阳,欧阳滢.干扰素中和抗体和CHB患者抗病毒疗效之间的关系[J].中外医疗,2010,29(26):31-32.DOI:10.3969/j.issn.1674-0742.2010.26.020.
[13]王卫兵,蔡雄,王国俊.a-干扰素治疗慢性乙型肝炎时自身抗体的变化及其临床意义[C].第五届全国肝脏疾病临床暨中华肝脏病杂志成立十周年学术会议论文汇编,大连:中华医学会肝病学分会,2006,124.
[14]郝洁,田小军,宋新文,等.聚乙二醇干扰素对慢性丙肝患者血清炎症细胞因子及抗体水平的影响[J].山东医药,2016,56(40):96-98.DOI:10.3969/j.issn.1002-266X.2016.40.033.
[15]吴琴,雷学忠,韦秀甜,等.自身抗体对慢性丙型病毒性肝炎疗效及安全性的影响[J].华西医学,2016,31(8):1363-1366.
[2]聂尚燕,赵蕾,麻慧宇,等.恩替卡韦联合聚乙二醇干扰素α-2a治疗慢性乙型病毒性肝炎的临床疗效及安全性[J].中国临床药理学杂志,2015,31(23):2281-2283.DOI:10.13699/j.cnki.1001-6821.2015.23.001.
[3]杨龙,杨阳,陈志勇,等.聚乙二醇干扰素α-2a治疗多种核苷(酸)类药物耐药慢性乙型肝炎的疗效[J].实用医学杂志,2014,30(3):503-504.DOI:10.3969/j.issn.1006-5725.2014.03.059.
[4]谢志伟,周福元,周元平.干扰素α和恩替卡韦治疗HBeAg阳性慢性乙型肝炎疗效的预测因素[J].南方医科大学学报,2013,33(6):878-881.DOI:10.3969/j.issn.1673-4254.2013.06.19.
[5]李剑萍,关玉娟,洪文昕,等.聚乙二醇干扰素联合利巴韦林治疗慢性丙型肝炎患者疗效及其影响因素分析[J].实用肝脏病杂志,2014,17(2):149-153.DOI:10.3969/j.issn.1672-5069.2014.02.010.
[6]张文杰,李朝霞,田淑菊,等.干扰素α治疗慢性丙型肝炎干扰素中和抗体的产生及其对抗病毒治疗疗效的影响[J].临床肝胆病杂志,2010,26(1):27-30.DOI:10.3969/j.issn.1001-5256.2010.01.008.
[7]王慧,林栋栋,李长缨,等.慢性乙型肝炎干扰素治疗与KIR基因多态性及干扰素抗体的相关性研究[J].中国医学创新,2017,14(6):20-24.DOI:10.3969/j.issn.1674-4985.2017.06.006.
[8]郑建铭,朱梦琪,陈明泉,等.聚乙二醇干扰素治疗慢性乙型肝炎患者血清干扰素浓度及其抗体水平的变化[J].肝脏,2012,17(12):840-842.DOI:10.3969/j.issn.1008-1704.2012.12.002.
[9]丁艾昆,郭利伟,欧阳瑞春,等.聚乙二醇干扰素a-2a联合核苷(酸)类似物治疗HBeAg阳性慢性乙型肝炎的疗效观察[J].中国病原生物学杂志,2015,10(3):272-276.DOI:10.13350/j.cjpb.150320.
[10]李茂英,袁学兰,张大志.聚乙二醇干扰素单用或联合核苷(酸)类似物治疗慢性乙型肝炎疗效与安全性的荟萃分析[J].中华肝脏病杂志,2012,20(6):442-447.DOI:10.3760/cma.j.issn.1007-3418.2012.06.013.
[11]屈晓威,庞秋霞,赵菊梅,等.延安市病毒性肝炎干扰素抗体的检测分析[J].延安大学学报(医学科学版),2009,7(3):3-4.DOI:10.3969/j.issn.1672-2639.2009.03.002.
[12]刘劲阳,欧阳滢.干扰素中和抗体和CHB患者抗病毒疗效之间的关系[J].中外医疗,2010,29(26):31-32.DOI:10.3969/j.issn.1674-0742.2010.26.020.
[13]王卫兵,蔡雄,王国俊.a-干扰素治疗慢性乙型肝炎时自身抗体的变化及其临床意义[C].第五届全国肝脏疾病临床暨中华肝脏病杂志成立十周年学术会议论文汇编,大连:中华医学会肝病学分会,2006,124.
[14]郝洁,田小军,宋新文,等.聚乙二醇干扰素对慢性丙肝患者血清炎症细胞因子及抗体水平的影响[J].山东医药,2016,56(40):96-98.DOI:10.3969/j.issn.1002-266X.2016.40.033.
[15]吴琴,雷学忠,韦秀甜,等.自身抗体对慢性丙型病毒性肝炎疗效及安全性的影响[J].华西医学,2016,31(8):1363-1366.